Biotron Ltd has released a press release.
Presentation of BIT225-009 hiv-1 phase 2 data
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- Response to ASX aware letter
- Biotron Secures $4.7 Million Underwriting Agreement
- $1.07 million R&D Tax Incentive Received
- Significant Immunological Outcomes in BIT225 HIV-1 Trial
- Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
Later from Biotron
- Presentation at BIO 2019
- Appointment of International Advisory Board for BIT225
- Presentation to Investors
- Biotron Secures $5.1 Million Underwriting Agreement
- Biotron to Test its Compounds Against Coronavirus
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron